Galectin Therapeutics Inc. (GALT) Financials
GALT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 22.2 million | 73.0 million |
2023-06-30 | 20.1 million | 71.2 million |
2023-03-31 | 20.2 million | 62.9 million |
2022-12-31 | 21.3 million | 53.5 million |
GALT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -7.6 million | 586000 |
2023-06-30 | -9.8 million | 516000 |
2023-03-31 | -10.8 million | 662000 |
2022-12-31 | -7.2 million | 681000 |
GALT Net Income
No data available :(
GALT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 20.4 million | - | 77000 |
2023-06-30 | 18.0 million | - | 43000 |
2023-03-31 | 17.8 million | - | 97000 |
2022-12-31 | 18.6 million | - | 40000 |
GALT Shares Outstanding
GALT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 7.7 million | 1.4 million | - |
2023-06-30 | - | 7.4 million | 1.6 million | - |
2023-03-31 | - | 8.8 million | 1.5 million | - |
2022-12-31 | - | 9.0 million | 1.6 million | - |
GALT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | - | 8000 |
2023-06-30 | - | - |
2023-03-31 | - | 32000 |
2022-12-31 | - | 8000 |
GALT
Price: $3.37
52 week price:
Earnings Per Share: -0.74 USD
P/E Ratio: -2.28
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Volume: 205300
Ebitda: -4.4 millionMarket Capitalization: 238.9 million